Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Activation of cGAS/STING signaling pathway has emerged as an attractive therapeutic strategy to enhance cancer immunotherapy efficacy. Actually, endogenous damaged double-stranded DNA (dsDNA) can intrinsically activate this pathway, but tumor resistance often arises through extensive DNA repair mechanisms. To overcome this challenge, we firstly developed ataxia telangiectasia mutated inhibitor (ATMi) loaded hollow-structured CuS nanoparticles with in situ surface growth of platinum nanoparticles (Pt-NPs; chemo-prodrugs), termed as HCuS@Pt@ATMi (HCuSPtA). Upon cellular internalization, the HCuS NPs mediate photothermal/photodynamic therapy (PTT/PDT), combined with ROS-activated Pt-NPs exert chemotherapeutic effects, synergistically inducing dsDNA damage in both nuclear and mitochondrial genomes. Crucially, the released ATMi disrupts DNA repair system through prohibiting the cell cycle checkpoint activation, leading to the accumulation of damaged dsDNA. These irreversible damaged dsDNA fragments not only activate the cGAS/STING pathway, but also serve as immunogenic damage-associated molecular patterns (DAMPs), promoting dendritic cell cross-presentation upon extracellular release. In vivo studies confirmed significant cytotoxic T lymphocyte infiltration and superior anti-tumor efficacy. By inducing dysfunctional DNA repair system to achieve irreversible dsDNA damage, this work provides a novel approach to augment cGAS/STING-mediated innate immunity, advancing combinatorial strategies for cancer immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2025.114075DOI Listing

Publication Analysis

Top Keywords

cancer immunotherapy
12
dna repair
12
cgas/sting-mediated innate
8
innate immunity
8
dsdna damage
8
repair system
8
damaged dsdna
8
dna
5
dsdna
5
augmenting cgas/sting-mediated
4

Similar Publications

Resolve and regulate: Alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor immunotherapy.

Biomaterials

September 2025

Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China. Electronic address:

The stimulator of interferon genes (STING) pathway represents a promising target in cancer immunotherapy. However, the clinical translation of cyclic dinucleotide (CDN)-based STING agonists remains hindered by insufficient formation of functional CDN-STING complexes. This critical bottleneck arises from two interdependent barriers: inefficient cytosolic CDN delivery and tumor-specific STING silencing via DNA methyltransferase-mediated promoter hypermethylation.

View Article and Find Full Text PDF

Wearable bioelectronics for skin cancer management.

Biomaterials

August 2025

Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA. Electronic address:

Wearable bioelectronics have transformed modern biomedical applications by enabling seamless integration with biological tissues, providing continuous, comprehensive, and personalized healthcare. Skin cancer, particularly melanoma, poses a significant clinical challenge due to its high metastatic potential and associated mortality. Traditional diagnostic approaches face limitations in accuracy, accessibility, and reproducibility, while existing treatments are often constrained by systemic toxicity and therapeutic resistance.

View Article and Find Full Text PDF

Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.

Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.

View Article and Find Full Text PDF

Purpose: Expanding high-risk human papillomavirus (HPV) vaccine coverage in resource-constrained settings is critical to bridging the cervical cancer gap and achieving the global action plan for elimination. Mobile health (mHealth) technology via short message services (SMS) has the potential to improve HPV vaccination uptake. The mHealth-HPVac study evaluated the effectiveness of mHealth interventions in increasing HPV vaccine uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria.

View Article and Find Full Text PDF

BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.

View Article and Find Full Text PDF